Press Release

Dr Barry Kenny joins as Non-Executive Director Dr Andrew Southan, COO, appointed Executive Director Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has appointed Dr Barry Kenny and Dr Andrew Southan to its Board of Directors. The appointments have been made to strengthen the Company’s focus [...]

Scientific Advisory Board will provide scientific oversight and strategic advice to support Metrion’s ion channel screening, cardiac safety testing, and native tissue and human stem cell translational assays. Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced that it has established a Science Advisory Board (SAB) to provide [...]

Metrion Biosciences awarded £200k funding under Innovate UK Biomedical Catalyst Feasibility Award Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease Project forms the first of a series designed to deliver proof of concept data on immune-sparing drug candidates Project will further enhance Metrion’s ion channel drug discovery [...]

Acquired intellectual property rights have potential application in a variety of clinical indications, including auto-immune disorders and neurodegenerative diseases. Metrion now owns all patented and unpatented IP developed during previous collaboration between Metrion and Japan Tobacco Inc. Cambridge, UK, 29 January 2018: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery [...]

Cambridge, UK, 16 January 2018: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and online investment platform SyndicateRoom, announced today the opening of a £600k investment round in Metrion. Metrion will use the funds to expand its rapidly growing fee-for-service business. This is the first private investment round for [...]